

JUL 25 2005 1:45PM AVENTIS US PAT DEPT
TO: US CENTRALIZED USPTO

RECEIVED
CENTRAL FAX CENTER

NO. 7048 P. 1

JUL 25 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	101796,466
	Filing Date	March 09, 2004
	First Named Inventor	Joachim BRENDDEL et al.
	Art Unit	1625
	Examiner Name	MORRIS, Patricia L.
	Attorney Docket Number	DEAV2003/0024 US NP
Total Number of Pages in This Submission	11	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Joseph D. Rossi		
Date	July 25, 2005	Reg. No.	47,038

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 11)			
Signature			
Typed or printed name	Paul Irvine	Date	July 25, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

JUL. 25. 2005 1:46PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 7048T P. 2

JUL 25 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
BRENDEL, et al.

Examiner: Morris, Patricia

Art Unit: 1625

Application No.: 10/796,466

Filed: March 9, 2004

Title: **2-(BUTYL-1-SULFONYLAMINO)-N-
[1(R)-(6-METHOXYPYRIDIN-3-
YL)PROPYL] BENZAMIDE, ITS USE
AS A MEDICAMENT, AND
PHARMACEUTICAL
PREPARATIONS COMPRISING IT**

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted
via facsimile to the Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, at 571-273-8300, on

July 25, 2005

Date of Deposit

Paul Irvine
Signature

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

REPLY PUSUANT TO 37 C.F.R. § 1.111

In response to the Office Action dated April 25, 2005 ("the Action"), reconsideration
is respectfully requested in view of the amendments and/or remarks as indicated below:

- Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.
- Remarks/Arguments begin on page 4 of this paper.